TN2009000082A1 - Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof - Google Patents

Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof

Info

Publication number
TN2009000082A1
TN2009000082A1 TN2009000082A TN2009000082A TN2009000082A1 TN 2009000082 A1 TN2009000082 A1 TN 2009000082A1 TN 2009000082 A TN2009000082 A TN 2009000082A TN 2009000082 A TN2009000082 A TN 2009000082A TN 2009000082 A1 TN2009000082 A1 TN 2009000082A1
Authority
TN
Tunisia
Prior art keywords
alkyl
pyridin
therapeutic use
pyrrolizine
quinolizine
Prior art date
Application number
TN2009000082A
Other languages
English (en)
Inventor
Gihad Dargazanli
Genevieve Estenne-Bouhtou
Florence Medaisko
Maria Carmen Renones
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of TN2009000082A1 publication Critical patent/TN2009000082A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TN2009000082A 2006-09-22 2009-03-10 Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof TN2009000082A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0608348A FR2906251B1 (fr) 2006-09-22 2006-09-22 Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique
PCT/FR2007/001545 WO2008037881A2 (fr) 2006-09-22 2007-09-21 Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique.

Publications (1)

Publication Number Publication Date
TN2009000082A1 true TN2009000082A1 (en) 2010-08-19

Family

ID=37897398

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2009000082A TN2009000082A1 (en) 2006-09-22 2009-03-10 Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof

Country Status (29)

Country Link
US (2) US7776880B2 (fr)
EP (1) EP2077837A2 (fr)
JP (1) JP2010504311A (fr)
KR (1) KR20090080947A (fr)
CN (1) CN101573113A (fr)
AR (1) AR062896A1 (fr)
AU (1) AU2007301880A1 (fr)
BR (1) BRPI0717100A2 (fr)
CA (1) CA2663080A1 (fr)
CL (1) CL2007002732A1 (fr)
CO (1) CO6160309A2 (fr)
CR (1) CR10658A (fr)
EA (1) EA015974B1 (fr)
FR (1) FR2906251B1 (fr)
GT (1) GT200900061A (fr)
HN (1) HN2009000504A (fr)
IL (1) IL197500A0 (fr)
MA (1) MA30790B1 (fr)
ME (1) MEP10109A (fr)
MX (1) MX2009003083A (fr)
NO (1) NO20091351L (fr)
NZ (1) NZ575573A (fr)
PE (1) PE20081376A1 (fr)
SV (1) SV2009003191A (fr)
TN (1) TN2009000082A1 (fr)
TW (1) TW200819455A (fr)
UY (1) UY30604A1 (fr)
WO (1) WO2008037881A2 (fr)
ZA (1) ZA200901850B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842804B1 (fr) 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861074B1 (fr) * 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
WO2010087762A1 (fr) * 2009-01-28 2010-08-05 Astrazeneca Ab Composés 2-aza-bicyclo[2.2.1]heptane et leurs utilisations
AR075182A1 (es) * 2009-01-28 2011-03-16 Astrazeneca Ab Compuestos 2-aza-biciclo (2.2.2) octano y sus usos
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US8143273B2 (en) * 2010-06-22 2012-03-27 Hoffman-La Roche Inc. Quinolizidine and indolizidine derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3801636A (en) 1971-08-13 1974-04-02 Abbott Lab 3,4,5-tri-substituted cinnamides
US4409225A (en) * 1981-03-16 1983-10-11 Beecham Group Limited Substituted benzamides
WO1993005040A1 (fr) * 1991-09-12 1993-03-18 Smithkline Beecham Plc Composes azacycliques utilises comme antagonistes du recepteur 5-ht¿4?
CZ284456B6 (cs) 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
EP1326863A2 (fr) * 2000-09-22 2003-07-16 Ortho-McNeil Pharmaceutical, Inc. Octahydro-indolizines et quinolizines et hexahydro-pyrrolizines
FR2861076B1 (fr) 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
FR2906251B1 (fr) 2008-11-07
SV2009003191A (es) 2009-10-27
GT200900061A (es) 2010-06-21
KR20090080947A (ko) 2009-07-27
CR10658A (es) 2009-06-24
MEP10109A (en) 2011-12-20
BRPI0717100A2 (pt) 2013-10-15
FR2906251A1 (fr) 2008-03-28
AR062896A1 (es) 2008-12-10
JP2010504311A (ja) 2010-02-12
EA015974B1 (ru) 2012-01-30
MA30790B1 (fr) 2009-10-01
CA2663080A1 (fr) 2008-04-03
NO20091351L (no) 2009-06-22
EP2077837A2 (fr) 2009-07-15
IL197500A0 (en) 2009-12-24
UY30604A1 (es) 2008-05-02
US7776880B2 (en) 2010-08-17
WO2008037881A2 (fr) 2008-04-03
AU2007301880A1 (en) 2008-04-03
CN101573113A (zh) 2009-11-04
NZ575573A (en) 2011-12-22
TW200819455A (en) 2008-05-01
HN2009000504A (es) 2011-10-20
WO2008037881A3 (fr) 2008-05-22
EA200970312A1 (ru) 2009-12-30
MX2009003083A (es) 2009-04-02
CL2007002732A1 (es) 2008-04-18
ZA200901850B (en) 2010-06-30
US20100267766A1 (en) 2010-10-21
CO6160309A2 (es) 2010-05-20
US20090258899A1 (en) 2009-10-15
PE20081376A1 (es) 2008-11-07

Similar Documents

Publication Publication Date Title
TN2009000082A1 (en) Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
MY145603A (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
EA200970656A1 (ru) Вич-ингибирующие 5,6-замещенные пиримидины
JP2011522866A5 (fr)
JP2007508359A5 (fr)
MY145408A (en) Dihydropyrazolopyrimidinone derivatives
AR070460A1 (es) Compuestos inhibidores de erk y composiciones farmaceuticas que los contienen
WO2003057688A3 (fr) Composes oxo ou oxy-pyridine utilises comme modulateurs du recepteur 5-ht4
NO20084129L (no) Pyridin(3,4-B)Pyrazinoner
JP2014525420A5 (fr)
WO2008126922A1 (fr) Composition d'agent nématicide et son procédé d'utilisation
JP2013507425A5 (fr)
RU2011129383A (ru) Производное амина, обладающее антагостической активностью в отношении рецептора npy y5
EA201791254A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
JP2012528166A5 (fr)
MX337906B (es) Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
TR201908590T4 (tr) Nitrokatekol türevlerini içeren farmasötik formülasyonlar ve bunların üretimine yönelik yöntemler.
JP2009528284A5 (fr)
HRP20160252T1 (hr) C-4" položaj supstituiranog derivata makrolida
JP2013506729A5 (fr)
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
MX2009004140A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
BRPI1009497A2 (pt) Derivados de n-[(6-aza-biciclo[3.2.1] oct-5-il)-aril- metil]-heterobenzamida, o respectivo preparo e a respectiva aplicação em terapêutica
NO20052338L (no) Pyrrolo[3,4-c]karbazol- og pyrido[2,3-b]pyrrolo[3,4-e]indolforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem